Returning from the 2024 American Academy of Ophthalmology Annual Meeting in Chicago, Dr Garg highlights several important studies on diabetic macular edema (DME). One key study focused on the effectiveness of 8 mg aflibercept, showing that while all patients benefited, those with previously treated DME might require more frequent dosing compared with treatment-naive patients.
Dr Garg also emphasized the promising long-term results of aflibercept over 3 years, which allowed patients to have fewer injections while maintaining good vision. Additionally, Dr Garg discussed the positive results of faricimab in underrepresented racial groups in the ELEVATUM study, as well as emerging treatments like gene therapy and studies addressing the impact of social determinants of health on eye care outcomes.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AAO 2024: Key Advances in Diabetic Macular Edema - Medscape - Oct 24, 2024.
Comments